From several sites:
Last week the U.S. Senate took testimony regarding a bill that gives a bit of oomph to the FDA.
The new bill includes a temporary ban on consumer advertising of newly approved drug. The FDA had issued a report that informed that that it simply cannot track the safety of new drugs, nor respond quickly to problems.
The bill would require pharmaceutical companies to devise safety plans for new drugs. It calls for more disclosure of the results of drug trials in human subjects. It also would give the FDA the authority to require companies to carry out safety studies of drugs once they are on the market.